Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jan;117(2):325–332. doi: 10.1111/j.1476-5381.1996.tb15194.x

Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogues.

L J Cross 1, A G Beck-Sickinger 1, M Bienert 1, W Gaida 1, G Jung 1, E Krause 1, M Ennis 1
PMCID: PMC1909254  PMID: 8789386

Abstract

1. Neuropeptide-induced histamine release is thought to occur via receptor-independent mechanisms, with net charge and lipophilicity being important factors. 2. In this study, the histamine releasing ability of neuropeptide Y (NPY), two C-terminal segments of NPY and 13 centrally truncated NPY analogues was examined. These results were compared with the ability of the peptides to bind to the Y2 receptor in the rabbit kidney membrane model and with their hypotensive actions in the anaesthetized-rat model. 3. All analogues tested, with the exception of [Glu4,25,33,35]-NPY(1-4)-Ahx-(25-36) and [Asp4,25,33,35]NPY(1-4)-Ahx-(25-36) which were devoid of histamine releasing activity, evoked a dose-dependent histamine release but there were marked differences between the peptides. The native peptide was the least active. 4. Histamine release was not linked to the ability of the peptides to displace NPY from Y2 receptors. There was a statistical correlation between the hypotensive effects expressed as ED10 values (mumol kg-1, which induced a blood pressure decrease of 10 mmHg) and the EC25 for histamine release (r = 0.62, P = 0.04), although histamine release may not be the sole determinant of the alterations in blood pressure. 5. There was a strong negative correlation between EC25 for histamine release and net positive charge (r = -0.93, P = 5.7 x 10(-7), i.e. increasing the net positive charge caused greater histamine release. However, there was a 12 fold difference in activity amongst the most positively charged analogues (+5). Helicity did not correlate with histamine releasing ability. 6. In the development of NPY-related drugs the avoidance of compounds with net positive charge is recommended.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J., Novotný J., Martin J., Heinrich G. Molecular structure of mammalian neuropeptide Y: analysis by molecular cloning and computer-aided comparison with crystal structure of avian homologue. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2532–2536. doi: 10.1073/pnas.84.8.2532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beck-Sickinger A. G., Dürr H., Jung G. Semiautomated T-bag peptide synthesis using 9-fluorenyl-methoxycarbonyl strategy and benzotriazol-1-yl-tetramethyl-uronium tetrafluoroborate activation. Pept Res. 1991 Mar-Apr;4(2):88–94. [PubMed] [Google Scholar]
  3. Beck-Sickinger A. G., Gaida W., Schnorrenberg G., Lang R., Jung G. Neuropeptide Y: identification of the binding site. Int J Pept Protein Res. 1990 Dec;36(6):522–530. doi: 10.1111/j.1399-3011.1990.tb00991.x. [DOI] [PubMed] [Google Scholar]
  4. Beck-Sickinger A. G., Grouzmann E., Hoffmann E., Gaida W., van Meir E. G., Waeber B., Jung G. A novel cyclic analog of neuropeptide Y specific for the Y2 receptor. Eur J Biochem. 1992 Jun 15;206(3):957–964. doi: 10.1111/j.1432-1033.1992.tb17006.x. [DOI] [PubMed] [Google Scholar]
  5. Beck-Sickinger A. G., Hoffmann E., Paulini K., Reissig H. U., Willim K. D., Wieland H. A., Jung G. High-affinity analogues of neuropeptide Y containing conformationally restricted non-proteinogenic amino acids. Biochem Soc Trans. 1994 Feb;22(1):145–149. doi: 10.1042/bst0220145. [DOI] [PubMed] [Google Scholar]
  6. Beck-Sickinger A. G., Jung G., Gaida W., Köppen H., Schnorrenberg G., Lang R. Structure/activity relationships of C-terminal neuropeptide Y peptide segments and analogues composed of sequence 1-4 linked to 25-36. Eur J Biochem. 1990 Dec 12;194(2):449–456. doi: 10.1111/j.1432-1033.1990.tb15638.x. [DOI] [PubMed] [Google Scholar]
  7. Beck-Sickinger A. G., Jung G. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers. 1995;37(2):123–142. doi: 10.1002/bip.360370207. [DOI] [PubMed] [Google Scholar]
  8. Beck-Sickinger A. G., Wieland H. A., Wittneben H., Willim K. D., Rudolf K., Jung G. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem. 1994 Nov 1;225(3):947–958. doi: 10.1111/j.1432-1033.1994.0947b.x. [DOI] [PubMed] [Google Scholar]
  9. Beck A., Jung G., Gaida W., Köppen H., Lang R., Schnorrenberg G. Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36. FEBS Lett. 1989 Feb 13;244(1):119–122. doi: 10.1016/0014-5793(89)81175-5. [DOI] [PubMed] [Google Scholar]
  10. Blundell T. L., Pitts J. E., Tickle I. J., Wood S. P., Wu C. W. X-ray analysis (1. 4-A resolution) of avian pancreatic polypeptide: Small globular protein hormone. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4175–4179. doi: 10.1073/pnas.78.7.4175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Blundell T., Wood S. The conformation, flexibility, and dynamics of polypeptide hormones. Annu Rev Biochem. 1982;51:123–154. doi: 10.1146/annurev.bi.51.070182.001011. [DOI] [PubMed] [Google Scholar]
  12. Chang R. S., Lotti V. J., Chen T. B., Cerino D. J., Kling P. J. Neuropeptide Y (NPY) binding sites in rat brain labeled with 125I-Bolton-Hunter NPY: comparative potencies of various polypeptides on brain NPY binding and biological responses in the rat vas deferens. Life Sci. 1985 Dec 2;37(22):2111–2122. doi: 10.1016/0024-3205(85)90583-1. [DOI] [PubMed] [Google Scholar]
  13. Darbon H., Bernassau J. M., Deleuze C., Chenu J., Roussel A., Cambillau C. Solution conformation of human neuropeptide Y by 1H nuclear magnetic resonance and restrained molecular dynamics. Eur J Biochem. 1992 Oct 15;209(2):765–771. doi: 10.1111/j.1432-1033.1992.tb17346.x. [DOI] [PubMed] [Google Scholar]
  14. Devillier P., Drapeau G., Renoux M., Regoli D. Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. Eur J Pharmacol. 1989 Sep 1;168(1):53–60. doi: 10.1016/0014-2999(89)90632-8. [DOI] [PubMed] [Google Scholar]
  15. Emadi-Khiav B., Mousli M., Bronner C., Landry Y. Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. Eur J Pharmacol. 1995 Jan 5;272(1):97–102. doi: 10.1016/0014-2999(94)00628-k. [DOI] [PubMed] [Google Scholar]
  16. Ennis M. Laboratory histamine measurements to study type I adverse allergic/pseudoallergic reactions to agents used in anaesthesia and surgery. Monogr Allergy. 1992;30:74–93. [PubMed] [Google Scholar]
  17. Fauchère J. L., Charton M., Kier L. B., Verloop A., Pliska V. Amino acid side chain parameters for correlation studies in biology and pharmacology. Int J Pept Protein Res. 1988 Oct;32(4):269–278. doi: 10.1111/j.1399-3011.1988.tb01261.x. [DOI] [PubMed] [Google Scholar]
  18. Fuhlendorff J., Gether U., Aakerlund L., Langeland-Johansen N., Thøgersen H., Melberg S. G., Olsen U. B., Thastrup O., Schwartz T. W. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci U S A. 1990 Jan;87(1):182–186. doi: 10.1073/pnas.87.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gaus H. J., Beck-Sickinger A. G., Bayer E. Optimization of capillary electrophoresis of mixtures of basic peptides and comparison with HPLC. Anal Chem. 1993 May 15;65(10):1399–1405. doi: 10.1021/ac00058a016. [DOI] [PubMed] [Google Scholar]
  20. Grundemar L., Krstenansky J. L., Håkanson R. Neuropeptide Y and truncated neuropeptide Y analogs evoke histamine release from rat peritoneal mast cells. A direct effect on G proteins? Eur J Pharmacol. 1994 Jun 2;258(1-2):163–166. doi: 10.1016/0014-2999(94)90071-x. [DOI] [PubMed] [Google Scholar]
  21. Grundemar L., Wahlestedt C., Shen G. H., Zukowska-Grojec Z., Håkanson R. Biphasic blood pressure response to neuropeptide Y in anesthetized rats. Eur J Pharmacol. 1990 Apr 10;179(1-2):83–87. doi: 10.1016/0014-2999(90)90404-t. [DOI] [PubMed] [Google Scholar]
  22. Hennessey J. P., Jr, Johnson W. C., Jr Information content in the circular dichroism of proteins. Biochemistry. 1981 Mar 3;20(5):1085–1094. doi: 10.1021/bi00508a007. [DOI] [PubMed] [Google Scholar]
  23. Hook W. A., Tsuji S., Siraganian R. P. Magainin-2 releases histamine from rat mast cells. Proc Soc Exp Biol Med. 1990 Jan;193(1):50–55. doi: 10.3181/00379727-193-42989. [DOI] [PubMed] [Google Scholar]
  24. Krause E., Beyermann M., Dathe M., Rothemund S., Bienert M. Location of an amphipathic alpha-helix in peptides using reversed-phase HPLC retention behavior of D-amino acid analogs. Anal Chem. 1995 Jan 15;67(2):252–258. doi: 10.1021/ac00098a003. [DOI] [PubMed] [Google Scholar]
  25. Krstenansky J. L., Buck S. H. The synthesis, physical characterization and receptor binding affinity of neuropeptide Y (NPY). Neuropeptides. 1987 Jul;10(1):77–85. doi: 10.1016/0143-4179(87)90091-6. [DOI] [PubMed] [Google Scholar]
  26. Repke H., Bienert M. Mast cell activation--a receptor-independent mode of substance P action? FEBS Lett. 1987 Sep 14;221(2):236–240. doi: 10.1016/0014-5793(87)80932-8. [DOI] [PubMed] [Google Scholar]
  27. SHORE P. A., BURKHALTER A., COHN V. H., Jr A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther. 1959 Nov;127:182–186. [PubMed] [Google Scholar]
  28. Shen G. H., Grundemar L., Zukowska-Grojec Z., Håkanson R., Wahlestedt C. C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents. Eur J Pharmacol. 1991 Nov 12;204(3):249–256. doi: 10.1016/0014-2999(91)90849-l. [DOI] [PubMed] [Google Scholar]
  29. Sun X., Edvinsson L., Hedner T. Histamine-independent modulation of the neuropeptide Y-induced pressor response by alpha-trinositol in the pithed rat. Pharmacol Toxicol. 1994 Dec;75(6):371–376. doi: 10.1111/j.1600-0773.1994.tb00377.x. [DOI] [PubMed] [Google Scholar]
  30. Tonan K., Kawata Y., Hamaguchi K. Conformations of isolated fragments of pancreatic polypeptide. Biochemistry. 1990 May 8;29(18):4424–4429. doi: 10.1021/bi00470a023. [DOI] [PubMed] [Google Scholar]
  31. Wahlestedt C., Reis D. J. Neuropeptide Y-related peptides and their receptors--are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 1993;33:309–352. doi: 10.1146/annurev.pa.33.040193.001521. [DOI] [PubMed] [Google Scholar]
  32. Wolfenden R., Andersson L., Cullis P. M., Southgate C. C. Affinities of amino acid side chains for solvent water. Biochemistry. 1981 Feb 17;20(4):849–855. doi: 10.1021/bi00507a030. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES